Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0EMQPK)
ADC Name
SYD1875
Synonyms
SYD1875
   Click to Show/Hide
Organization
Byondis (Originator)
Drug Status
Phase 1 (discontinued)
Drug-to-Antibody Ratio
1.9
Structure
Antibody Name
SYD1594
  Antibody Info 
Antigen Name
Trophoblast glycoprotein (TPBG)
  Antigen Info 
Payload Name
Seco-DUBA
  Payload Info 
Payload Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
  Linker Info 
Conjugate Type
Reactive Cysteines
Combination Type
duocarmazine
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Unspecific solid tumor
1 Trials
Clinical trial identifier
NCT04202705
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04202705
PHASE1
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours

   Click to Show/Hide
Undisclosed  NCT04202705
Phase 1
A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Inclusion: Histologically-confirmed advanced/metastatic cancer (Part 1: any solid tumor; Part 2: 3 predefined cohorts) with 5T4 membrane staining, ECOG ≤1, adequate organ function (Part 2 requires measurable disease). Exclusion: Prior 5T4/SYD985 therapy, recent anticancer/hormone therapy (4w/1w), active keratitis/significant organ dysfunction, symptomatic brain metastases or treatment within 8w.

   Click to Show/Hide
Administration Dosage
SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Related Clinical Trial
NCT Number NCT04202705  Clinical Status PHASE1
Clinical Description A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours
Primary Endpoint
Incidence of dose-limiting toxicities
Other Endpoint
Objective response rate
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT04202705  Clinical Status Phase 1
Clinical Description A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours.
References
Ref 1 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
Ref 2 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours